MAAT INDEX

CLAIM #69714 · CVS Health Corp (CVS) · 2026Q2 earnings call · Aug 5, 2026 · due Dec 31, 2028

I'll take you back to Investor Day, and we always saw multiple pathways to achieving our target of a mid-teens EPS CAGR. And I think if you look at this year, Mike, based on the strength of our performance across the enterprise, we remain very confident in our commitment through 2028.

Brian O. Newman · CFO

PENDING
graded after results covering Dec 31, 2028 are reported

In context

Brian Newman (Chief Financial Officer): Thanks, David. And Mike, thanks for the question. I'll take you back to Investor Day, and we always saw multiple pathways to achieving our target of a mid-teens EPS CAGR. And I think if you look at this year, Mike, based on the strength of our performance across the enterprise, we remain very confident in our commitment through 2028. So at a high level that mid-teens goal remains intact. And I think it's too early in our planning process for specifics on 2027, given some of the dynamics that we're seeing early in the year; we just wanted to provide some commentary and pull forward the conversation by about a quarter. So I would reiterate, confident in our ability to generate highly attractive earnings growth at the enterprise level next year in 2027. I think a reasonable floor for 2027 for adjusted EPS could be $8.44, and that's obviously consistent with current consensus. It would imply an EPS growth rate for us of about 13% off of that adjusted baseline of $7.46. And just to remind you, the baseline reflects the midpoint of our updated EPS guide and then, consistent with our guidance convention, it excludes prior year development and any prior year items in our individual exchange business, which we've exited. One thing I think worth emphasizing is the strong cash flow generation of the enterprise. It was demonstrated again this quarter. We continue to strengthen our balance sheet. And as a reminder, we've only reflected the offset of dilution in our long-term expectations. So the expectations continue to be grounded in a guidance philosophy of establishing credible targets, delivering with disciplined execution and highlighting opportunities for outperformance. Prem, do you want to talk more about the dynamics within the business?

Verify independently

SEC filings for CVS · Claim quote is verbatim from the 2026Q2 earnings call.